#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Journal of Czech Physicians / 2018 - 5

Treatment of tobacco dependence as a standard part of oncology care

Czech version

Authors: Eva Králíková 1,2;  Alexandra Pánková 1,2;  Kamila Zvolská 2;  František Perlík 3
Authors‘ workplace: Ústav hygieny a epidemiologie 1. LF UK a VFN v Praze 1;  Centrum pro závislé na tabáku 3. interní kliniky – kliniky endokrinologie a metabolismu 1. LF UK a VFN v Praze 2;  Farmakologický ústav 1. LF UK a VFN v Praze 3
Published in: Čas. Lék. čes. 2018; 157: 244-247
Category: Review Article

Overview

After the oncological diagnosis, smoking has a major impact on survival, course and effectiveness of oncology treatment, and quality of the further life. Smoking worsens surgery outcomes, reduces the effectiveness of radiation therapy and chemotherapy, increases the risk of side effects of oncology treatment, and increases the incidence of tumor duplication or other comorbidities like venous thrombosis, cardiovascular diseases or infections.

The article contains a summary of practical recommendations for oncology patients, including smoke-free environments, the importance of zero exposure to tobacco smoke, clear advice to stop smoking to smokers and offer of tobacco dependence treatment. Except of brief intervention within few tens of seconds up to 10 minutes, intensive treatment should be available, for example in special tobacco-dependence centers. In the documentation smoking status should be recorded including exposure to passive smoking, interventions to smokers (both active and passive) should be empathically repeated. The motivation to treat tobacco dependence should be mainly related to their specific oncological diagnosis, prognosis, course and effectiveness of its treatment.

Treatment of tobacco dependence should be an obvious part of quality oncological care by doctors and nurses in intensity according to their time availability.

Keywords:

tobacco smoking, smoking cessation, nicotine dependence, chemotherapy, pharmacological interactions, adverse effects, cancer

Sources
  1. Warren GW, Cummings KM. Tobacco and lung cancer: risks, trends, and outcomes in patients with cancer. Am Soc Clin Oncol Educ Book 2013: 359–364.
  2. Poghosyan H, Sheldon LK, Leveille SG, Cooley ME. Health-related quality of life after surgical treatment in patients with non-small cell lung cancer: a systematic review. Lung Cancer 2013; 81(1): 11–26.
  3. Hymowitz N. Smoking and cancer: a review of public health and clinical implications. J Natl Med Assoc 2011; 103(8): 695–700.
  4. Petros WP, Younis IR, Ford JN, Weed SA. Effects of tobacco smoking and nicotine on cancer treatment. Pharmacotherapy 2012; 32(10): 920–31.
  5. Weaver KE, Danhauer SC, Tooze JA et al. Smoking cessation counseling beliefs and behaviors of outpatient oncology providers. Oncologist 2012; 17(3): 455–62.
  6. Schroeder SA. An update about tobacco and cancer: what clinicians should do know. J Cancer Educ 2012; 27(1): 5–10.
  7. Florou AN, Gkiozos IC, Tsagouli SK et al. Clinical significance of smoking cessation in subjects with cancer: a 30-year review. Respir Care 2014; 59(12): 1924–1936.
  8. Sørensen LT, Hørby J, Friis E et al. Smoking as a risk factor for wound healing and infection in breast cancer surgery. Eur J Surg Oncol 2002 Dec; 28(8): 815–820.
  9. Warren GW, Sobus S, Gritz ER. The biological and clinical effects of smoking by patients with cancer and strategies to implement evidence-based tobacco cessation support. Lancet Oncol 2014; 15(12): e568–e580.
  10. O’Malley M, King AN, Conte M et al. Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer. J Thorac Oncol 2014; 9(7): 917–926.
  11. Gritz ER, Dresler C, Sarna L. Smoking, the missing drug interaction in clinical trials: ignoring the obvious. Cancer Epidemiol Biomarkers Prev 2005; 14(10): 2287–2293.
  12. Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. Clin Pharmacokinet 1999; 36: 425–438.
  13. Hamilton M, Wolf JL, Rusk J et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006; 12: 2166–2171.
  14. Duckett DR, Cameron MD. Metabolism considerations for kinase inhibitors in cancer treatment. Expert Opin Drug Metab Toxicol 2010; 6: 1175–1193.
  15. van der Bol JM, Mathijssen RH, Loos et al. Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J Clin Oncol 2007; 25(19): 2719–2726.
  16. de Graan AJ, Loos WJ, Friberg LE et al. Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy. Clin Cancer Res 2012; 18: 4425–4432.
  17. O’Malley M, Healy P, Daignault S, Ramnath N. Cigarette smoking and gemcitabine-induced neutropenia in advanced solid tumors. Oncology 2013; 85(4): 216–222.
  18. Kanai M, Morita S, Matsumoto S et al. A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia. Ann Oncol 2009; 20: 1397–1401.
  19. Sohn HS, Kwon JW, Shin S et al. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis. J Clin Pharm Ther 2015; 40(6): 661–671.
  20. de Jong FA, Sparreboom A, Verweij J, Mathijssen RH. Lifestyle habits as a contributor to anti-cancer treatment failure. Eur J Cancer 2008; 44(3): 374–382.
  21. Condoluci A, Mazzara C, Zoccoli A et al. Impact of smoking on lung cancer treatment effectiveness: a review. Future Oncol 2016; 12(18): 2149–2161.
  22. Peppone LJ, Mustian KM, Morrow GR et al. The effect of cigarette smoking on cancer treatment-related side effects. Oncologist 2011; 16(12): 1784–1792.
  23. Ajili F, Kourda N, Karay S et al. Impact of smoking intensity on outcomes of patients with non muscle invasive bladder cancer treated by BCG immunotherapy. Ultrastruct Pathol 2013; 37(4): 273–277.
  24. Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ 2010; 340: b5569.
  25. Warren GW, Reid ME, Cummings KM, Marshall JR. Author's reply to: Smoking at diagnosis and survival in cancer patients. Int J Cancer 2013; 132(4): 992.
  26. Štěpánková L, Králíková E, Zvolská K et al. Depression and smoking cessation: evidence from a smoking cessation clinic with 1-year follow-up. Ann Behav Med 2017; 51(3): 454–463.
  27. Králíková E. Kouření zdravotníků. In: Králíková E. Závislost na tabáku – epidemiologie, prevence a léčba. Adamira, Břeclav, 2013: 63–64.
  28. WHO. Mezinárodní klasifikace nemocí, 10. Verze. WHO, Geneva, 1992.
  29. Fiore MC, Bailey WC, Cohen SJ et al. Treating Tobacco Use and Dependence: 2008 Update. (2008). Clinical Practice Guideline. US Department of Health and Human Services. Public Health Service; May 2008.
  30. Králíková E, Češka R, Pánková A et al. Doporučení pro léčbu závislosti na tabáku. Vnitřní lékařství 2015; 61(5, Suppl 1): 1S4–1S15.
  31. McRobbie H, Bullen C, Glover M et al.; New Zealand Guidelines Group: New Zealand smoking cessation guidelines. N Z Med J 2008; 121(1276): 57–70.
  32. Shields PG. New NCCN Guidelines: Smoking Cessation for Patients with Cancer. J Natl Compr Canc Netw 2015; 13(5 Suppl): 643–645.
  33. Cummings M et al. Tobacco Cessation Guide for Oncology Providers, American Society of Clinical Oncology, 2012.
  34. Nayan S, Gupta MK, Strychowsky JE, Sommer DD. Smoking cessation interventions and cessation rates in the oncology population: an updated systematic review and meta-analysis. Otolaryngol Head Neck Surg 2013; 149(2): 200–211.
  35. Smith RA, Andrews KS, Brooks D et al. Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2017; 67(2): 100–121.
  36. Sarna L, Bialous SA. Implementation of tobacco dependence treatment programs in oncology settings. Semin Oncol Nurs 2016; 32(3): 187–196.
  37. Hughes J. Minnesota Tobacco Withdrawal Scale, 2003. Dostupné na: www.med.uvm.edu/behaviorandhealth/research/minnesota-tobacco-withdrawal-scale; česky na: www.slzt.cz/minnesotska-skala-abstinencnich-priznaku
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management
Lung cancer
Idiopathic pulmonary fibrosis: Does the time for change of diagnostic and therapeutic recommendations come?
Alcohol as an issue of the public health in the Czech Republic: facts and context
The origin and development of fat droplet and its role in health and illness
Aulus Cornelius Celsus and a regimen
Article was published in

Journal of Czech Physicians

Issue 5
2018 Issue 5
Download issue PDF
Most read in this issue
Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#